PanC-YOUNG: Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

• Sponsor: Azienda Ospedaliera Universitaria Integrata Verona (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05845801
• Collaborator: (none)
• Enrollment: 3,000
• Location: 1
• Anticipated Duration (Months): 357.8
• Patients Per Site Per Month: 8.4

Study Details

Study Description

Brief Summary

The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.

Condition or Disease	Intervention/Treatment	Phase
PDAC - Pancreatic Ductal Adenocarcinoma	Other: Register

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 3000 participants
• Observational Model: Other
• Time Perspective: Prospective
• Official Title: Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
• Actual Study Start Date: Dec 7, 2022
• Anticipated Primary Completion Date: Sep 30, 2052
• Anticipated Study Completion Date: Sep 30, 2052

Outcome Measures

Primary Outcome Measures

1. Register of young PDAC patients [30 years]

   Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 55 Years
• Sexes Eligible for Study: All

Inclusion Criteria:

• Age ≤55 years old at the time of diagnosis of pancreatic cancer

• Age ≥ 18 years

• Written informed consent obtained.

Exclusion Criteria:

• Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor)

• Absence of informed consent.

• Age < 18 years or > 55 years old at the time of diagnosis of pancreatic cancer

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	AOUI Verona	Verona		Italy	37134

Sponsors and Collaborators

• Azienda Ospedaliera Universitaria Integrata Verona

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Azienda Ospedaliera Universitaria Integrata Verona
• ClinicalTrials.gov Identifier: NCT05845801
• Other Study ID Numbers: 3968
• First Posted: May 6, 2023
• Last Update Posted: May 6, 2023
• Last Verified: May 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of May 6, 2023